NEWS
Genetic Study Reveals Clues to Pancreatic Neuroendocrine Tumors
Researchers at the Johns Hopkins Kimmel Cancer Center have sequenced DNA from patients with an uncommon form of pancreatic cancer to produce the first overview of the genetic basis of the disease, called neuroendocrine tumors. The investigators identified several genes that may provide prognostic information, as well as mutations in genes in a signaling pathway for which targeted therapies currently exist. Read more > >
Trial Suggests New Treatment Option for Gastrointestinal Stromal Tumors
Multi-targeted drug may be useful in tumors that have developed resistance to other treatmentsGene Test for Risk of Colorectal Cancer Recurrence Validated
Test could identify patients who may need or could avoid chemotherapyNewly Discovered Mutations May Help Drive Common Kidney Cancer
Further studies needed to understand the gene’s role in tumor formationInterferon-gamma Promotes UV-Induced Melanoma in a Mouse Model
If the relationship holds true in humans, it could lead to new treatments for some patients
COMMENTARY
A Conversation with Dr. Angela Mariotto and Dr. Martin Brown on the Rising Costs of Cancer Care
The two researchers from NCI’s Division of Cancer Control and Population Sciences spoke about a study published earlier this month in JNCI and how we may be able to address the looming issue of caring for a growing population of cancer survivors. Read more > >
IN DEPTH
Can Aspirin Reduce Cancer Risk and Mortality?
As optimism for aspirin’s apparent anticancer effects grows, unanswered questions remain
Seeking Better Treatments for Brain Tumors in Children
Three studies describe biologically distinct forms of medulloblastoma
Featured Clinical Trial: Dose-Adjusted Chemotherapy for Untreated c-MYC-Positive Lymphomas
Will dose-adjusted EPOCH-R be safe and effective in patients with c-MYC-positive NHL?
NCI Director Provides Update on New Programs and Initiatives
Director highlights priority areas for funding and unveils a new project to address provocative questions in cancer research
UPDATES
FDA Update
- FDA Updates Safety Review of Diabetes Drug for Possible Cancer Risk
Notes
- In Memoriam: Arthur Schatzkin, Branch Chief in DCEG
- New Program Aims to Help Businesses Navigate Regulatory Clearance for Products
- New Issue of CCR Connections Published
- State Cancer Legislative Database Adds Obesity Prevention
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.
